Sign Up to like & get
recommendations!
0
Published in 2021 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-0809
Abstract: Purpose: The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600 mutation–positive advanced melanoma.…
read more here.
Keywords:
advanced melanoma;
cobimetinib plus;
plus vemurafenib;
brafv600 mutation ... See more keywords